SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories - Quaterly Results

31 Jul 2025 Evaluate
The sales for the June 2025 quarter moved down -33.40% to Rs. 2927.53 millions as compared to Rs. 4396.02 millions during the year ago period.A radical decline of -86.06% was reported in the net profit of the company for the quarter ended June 2025 to Rs. 137.08  millions from Rs. 983.41 millions.Operating profit for the quarter ended June 2025 decreased to 421.49 millions as compared to 1286.33 millions of corresponding quarter ended June 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 2927.53 4396.02 -33.40 2927.53 4396.02 -33.40 14768.37 15585.80 -5.24
Other Income 78.56 48.07 63.43 78.56 48.07 63.43 205.09 125.44 63.50
PBIDT 421.49 1286.33 -67.23 421.49 1286.33 -67.23 3428.08 4744.65 -27.75
Interest 45.83 26.70 71.65 45.83 26.70 71.65 82.96 139.97 -40.73
PBDT 375.66 1465.89 -74.37 375.66 1465.89 -74.37 4109.16 4604.68 -10.76
Depreciation 201.87 162.79 24.01 201.87 162.79 24.01 655.42 596.99 9.79
PBT 173.79 1303.10 -86.66 173.79 1303.10 -86.66 3453.74 4007.69 -13.82
TAX 36.71 319.69 -88.52 36.71 319.69 -88.52 859.48 1011.73 -15.05
Deferred Tax -6.96 13.89 -150.11 -6.96 13.89 -150.11 122.95 15.87 674.73
PAT 137.08 983.41 -86.06 137.08 983.41 -86.06 2594.26 2995.96 -13.41
Equity 129.01 129.01 0.00 129.01 129.01 0.00 129.01 129.01 0.00
PBIDTM(%) 14.40 29.26 -50.80 14.40 29.26 -50.80 23.21 30.44 -23.75

Neuland Laboratories Share Price

17151.80 191.85 (1.13%)
09-Jun-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1780.50
Dr. Reddys Lab 1268.75
Cipla 1376.75
Zydus Lifesciences 1106.10
Lupin 2257.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×